OpenAI has acquired Orchestra Bio, a platform that helps biopharma teams coordinate the complex process of drug development. The company is bringing Orchestra's team and technology together with Rosalind, its AI models and tools for life sciences research. The goal is to help scientists make discoveries and manage the work needed to turn them into treatments that reach patients sooner.
Developing a new medicine is extraordinarily complex, taking roughly 10 to 15 years on average from target discovery to regulatory approval in the United States. Teams must orchestrate programs across internal departments and external partners, often relying on disconnected systems. OpenAI says AI can now help take on these specialized tasks and complex workflows.
Rosalind brings OpenAI's AI models to life sciences researchers. GPT-Rosalind helps scientists reason through questions in biology and chemistry, while Rosalind Workbench connects those capabilities with scientific tools and data to help researchers analyze results and plan experiments. Orchestra brings a team with experience across biotech, software, and AI, along with a platform built to coordinate drug development. Together, the companies aim to build agents that connect scientific findings with the studies, decisions, and next steps needed to advance a potential medicine.
Orchestra's platform lets people and AI agents work together on drug programs. Agents monitor and track studies, helping teams identify which activities and timelines are affected when a problem arises, such as a failed manufacturing batch that could delay a clinical trial. OpenAI is also working with Novo Nordisk on faster R&D and commercial execution, and with Moderna on translating complex data into experimental workflows. The company's vision is for AI to support scientists across the full process of discovering and developing new medicines.
Source: OpenAI Blog · Summarized by HeadlinesBriefing